Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2021-12-23 Major Shareholding Noti…
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (articles L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds'. It explicitly states that the US company Armistice Capital, LLC crossed below the 5% threshold of capital and voting rights in MAUNA KEA TECHNOLOGIES on December 16, 2021. This type of filing, reporting changes in significant share ownership levels crossing regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and contains specific regulatory reporting details, confirming it is a direct filing rather than an announcement of a filing.
2021-12-23 French
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 98% confidence The document is a press release dated December 13, 2021, announcing a strategic repositioning, changes in senior management (CEO resignation and interim appointment), and future focus areas. This content directly relates to changes in the company's leadership structure and strategic direction. This aligns best with the 'Board/Management Information' category (MANG), which covers announcements of changes in the company's board of directors or senior management. It is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2021-12-13 French
Inside Information / Other news releases
Board/Management Information Classification · 99% confidence The document is a press release dated December 13, 2021, announcing a 'Strategic Realignment,' including the resignation of the CEO and the appointment of an Interim CEO. This content directly relates to changes in senior management and the board structure. This aligns perfectly with the definition for Board/Management Information (MANG). It is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2021-12-13 English
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is a press release dated November 17, 2021, announcing a new peer-reviewed publication regarding the economic benefits of the company's product, Cellvizio®. It details the findings of a study published in *Techniques and Innovations in Gastrointestinal Endoscopy (TIGE)*. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about external research/data supporting the product, which falls under general investor communication. Since it is a press release announcing positive news/data rather than a specific regulatory event (like a dividend, management change, or transaction), it best fits the 'Regulatory Filings' (RNS) category as a general announcement, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but as a news release, RNS is the most appropriate general category for non-standard announcements.
2021-11-17 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated November 17, 2021, announcing the publication of a new study demonstrating the economic advantage of the company's product (Cellvizio) for pancreatic cyst management. It details the findings of a peer-reviewed journal article ('Cost-Benefit Analysis and Resource Implications of Endoscopy Ultrasound-guided Confocal Endomicroscopy in Pancreas Cysts' published in TIGE). Since the document is an announcement about new research findings and financial/clinical benefits, and not the full financial report (10-K, IR) or the transcript of an earnings call (CT), it best fits the category for general company news or updates that are not strictly regulatory filings, management changes, or dividend notices. Given the options, this is a general corporate announcement regarding clinical/economic validation. It is not a formal Earnings Release (ER) which focuses on period results, nor is it a specific regulatory filing like a DIRS or DEF 14A. It is most closely aligned with a general announcement, which often falls under Regulatory Filings (RNS) if no better fit exists, or potentially an Investor Presentation (IP) if it were a slide deck, but here it is a press release detailing new data. Since it is a press release announcing positive clinical/economic data, and not a formal regulatory filing like a 10-K or a specific financial report, RNS (Regulatory Filings - general fallback) is the most appropriate classification for a non-standard announcement of this nature, although it shares characteristics with an Investor Presentation (IP) in terms of content focus. However, RNS serves as the best catch-all for press releases detailing non-mandatory disclosures like new study results.
2021-11-17 French
Franchissement de seuil
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuil (articles L. 233-7 du code de commerce)" which translates to "Declaration of crossing a threshold". It explicitly states that the US company Armistice Capital, LLC crossed below the 10% threshold of the capital of MAUNA KEA TECHNOLOGIES on November 2, 2021, and now holds 9.95% of the capital. This type of filing, reporting changes in significant share ownership by crossing predefined thresholds (like 5%, 10%, etc.), corresponds directly to the definition of Major Shareholding Notification (MRQ). The document length is short (1592 chars), but the content is the declaration itself, not an announcement of a separate report.
2021-11-05 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.